Latest Insider Transactions at Syndax Pharmaceuticals Inc (SNDX)
This section provides a real-time view of insider transactions for Syndax Pharmaceuticals Inc (SNDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Syndax Pharmaceuticals Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Syndax Pharmaceuticals Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 29
2022
|
Peter Ordentlich Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
265
+50.0%
|
$3,710
$14.12 P/Share
|
|
Jul 25
2022
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
31,602
-46.47%
|
$663,642
$21.06 P/Share
|
|
Jul 25
2022
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,602
+31.6%
|
$189,612
$6.38 P/Share
|
|
Jul 07
2022
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100
-0.56%
|
$2,100
$21.0 P/Share
|
|
Jul 07
2022
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.56%
|
$600
$6.38 P/Share
|
|
Jul 06
2022
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,009
-45.94%
|
$315,189
$21.07 P/Share
|
|
Jul 06
2022
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,009
+31.48%
|
$90,054
$6.38 P/Share
|
|
Jul 01
2022
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
62,292
-77.74%
|
$1,183,548
$19.0 P/Share
|
|
Jul 01
2022
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
62,292
+43.74%
|
$436,044
$7.2 P/Share
|
|
Jun 13
2022
|
Keith A. Goldan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,205
+50.0%
|
-
|
|
Apr 04
2022
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
3,128
-14.92%
|
$56,304
$18.29 P/Share
|
|
Apr 04
2022
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
3,128
+12.98%
|
$31,280
$10.9 P/Share
|
|
Apr 01
2022
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
101,045
-50.03%
|
$1,717,765
$17.45 P/Share
|
|
Apr 01
2022
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
70,545
+44.39%
|
$705,450
$10.9 P/Share
|
|
Feb 02
2022
|
Martin H. Huber Jr. |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
-
|
|
Feb 02
2022
|
William Meury |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Jennifer Jarrett |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Fabrice Egros |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Pierre Legault |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Keith Katkin |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+33.33%
|
-
|
|
Feb 02
2022
|
Dennis Podlesak |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+29.69%
|
-
|
|
Feb 01
2022
|
Alexander Nolte Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
968
-100.0%
|
$15,488
$16.65 P/Share
|
|
Feb 01
2022
|
Peter Ordentlich Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,412
-100.0%
|
$22,592
$16.65 P/Share
|
|
Jan 31
2022
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
1,714
+6.86%
|
$20,568
$12.39 P/Share
|
|
Jan 31
2022
|
Alexander Nolte Chief Accounting Officer |
BUY
Other acquisition or disposition
|
Direct |
968
+50.0%
|
$11,616
$12.39 P/Share
|
|
Jan 31
2022
|
Peter Ordentlich Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
1,412
+50.0%
|
$16,944
$12.39 P/Share
|
|
Dec 30
2021
|
Michael L. Meyers SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,900
+21.48%
|
$47,200
$8.77 P/Share
|
|
Dec 22
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
24,000
-60.0%
|
$528,000
$22.01 P/Share
|
|
Dec 22
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+37.5%
|
$168,000
$7.88 P/Share
|
|
Dec 20
2021
|
Pierre Legault |
SELL
Open market or private sale
|
Direct |
20,000
-55.56%
|
$420,000
$21.01 P/Share
|
|
Dec 20
2021
|
Pierre Legault |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+35.71%
|
$140,000
$7.08 P/Share
|
|
Dec 20
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
61,000
-59.68%
|
$1,220,000
$20.29 P/Share
|
|
Dec 20
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
61,000
+37.01%
|
$427,000
$7.58 P/Share
|
|
Dec 17
2021
|
Briggs Morrison |
SELL
Open market or private sale
|
Direct |
35,156
-42.11%
|
$703,120
$20.0 P/Share
|
|
Dec 17
2021
|
Briggs Morrison |
BUY
Exercise of conversion of derivative security
|
Direct |
35,156
+29.63%
|
$351,560
$10.9 P/Share
|
|
Dec 17
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,676
-8.67%
|
$31,844
$19.02 P/Share
|
|
Dec 17
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,676
+7.98%
|
$10,056
$6.38 P/Share
|
|
Dec 16
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
22,715
-56.26%
|
$431,585
$19.08 P/Share
|
|
Dec 16
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,715
+36.0%
|
$136,290
$6.38 P/Share
|
|
Dec 13
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,609
-38.28%
|
$695,571
$19.05 P/Share
|
|
Dec 13
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,609
+24.61%
|
$219,654
$6.79 P/Share
|
|
Nov 18
2021
|
Fabrice Egros |
SELL
Open market or private sale
|
Direct |
14,030
-23.43%
|
$252,540
$18.03 P/Share
|
|
Nov 18
2021
|
Fabrice Egros |
BUY
Exercise of conversion of derivative security
|
Direct |
14,030
+16.0%
|
$112,240
$8.41 P/Share
|
|
Oct 26
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,296
-47.99%
|
$309,624
$19.2 P/Share
|
|
Oct 26
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,296
+32.43%
|
$114,072
$7.2 P/Share
|
|
Oct 25
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
44,704
-71.68%
|
$849,376
$19.13 P/Share
|
|
Oct 25
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,704
+41.75%
|
$312,928
$7.2 P/Share
|
|
Oct 05
2021
|
Dennis Podlesak |
BUY
Other acquisition or disposition
|
Direct |
463
+1.05%
|
-
|
|
Sep 27
2021
|
Michael A Metzger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,437
-58.05%
|
$464,303
$19.51 P/Share
|
|
Sep 27
2021
|
Michael A Metzger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,437
+36.73%
|
$171,059
$7.2 P/Share
|